Dr. Torsten Neuefeind
CEO
Prof. Dr. Robert Huber
Co-Founder
In 1988, Robert Huber received the highest honor the world of science has to bestow: together with Hartmut Michel and Johann Deisenhofer, he received the Nobel Prize in Chemistry “for the determination of the three-dimensional structure of a photosynthetic reaction center”. He studied for his doctorate and post-doctoral qualification in Chemistry at the TUM, to which he remained attached as director of the Max-Planck-Institute for Biochemistry.
He began to focus on crystallography for his dissertation and established a protein crystallography laboratory in the early 1970s. With the help of X-Ray Crystallography, he was able to demonstrate the structure of numerous proteins and protein complexes. These include: protease and their natural and synthetic inhibitors, metalloenzymes, immune system proteins, protein hormones and their receptors, protein kinases, amino acid biosynthesis enzymes, and energy and electron transfer proteins.
Robert Huber is a guest professor at the Universitat Autònoma de Barcelona, the University of Duisburg-Essen, Cardiff University in the UK, and Seoul National University in Korea.
Prof. Eric P. Pâques
Board Member
Eric P. Pâques is Non-Executive Chairman of the Supervisory Board of Proteros Biostructures GmbH (Munich, Germany) since 2014, chairman of the Board of Directors of Novadip Biosciences (Belgium) and Board member of Epics Therapeutics (Belgium) and of PL Bioscience (Germany) as well as of several academic and charity organizations. He was Independent Director of INC Research Inc., later Syneos Health, (USA), and Vice-Chairman of the Supervisory Board of the Grünenthal Group (Germany). He served more than 35 years in management positions in the pharmaceutical industry, thereof 20 years as General Manager / CEO of the Grünenthal Group. He is professor at the RWTH-Aachen University (Germany) and holds a Master degree and a PhD in Chemistry (University of Louvain, Belgium).
Dr. Horst Hemmerle
Chief Scientific Officer
Dr. Horst Hemmerle has over 30 years of leadership in drug discovery, spanning medicinal chemistry, pharmacology, and cutting-edge drug discovery technologies. He has guided many drug candidate programs across diverse therapeutic areas.
Before joining Proteros, Horst served as Senior Vice President and Chief Scientific Officer at Kojin Therapeutics, where he advanced novel approaches in the programmed cell death pathway area. His previous roles include Executive Director of Global Discovery Chemistry at the Novartis Institutes for Biomedical Research, Senior Director of Quantitative Biology and Lead Generation at Eli Lilly, and Head of Medicinal Chemistry at Aventis.
As CSO of Proteros, Horst leads the expansion of the company’s drug discovery capabilities, supporting its mission to help partners "reach right faster" through scientific excellence and innovation.
Dr. Tobias Gabriel
Chief Growth Officer
Dr. Tobias Gabriel serves as Chief Growth Officer at Proteros Biostructures, bringing over 25 years of global leadership experience in drug discovery and biochemistry.
Before joining Proteros, he was Vice President and Head of Europe at WuXi AppTec, and previously held senior executive roles at Novartis and Roche across Switzerland, the US, and China. Tobias plays a key role in driving strategic growth initiatives, with a particular focus on AI-enabled lead discovery. His expertise spans drug design, chemistry, ADME, and biochemistry – empowering teams to accelerate discovery pipelines.
Tobias is passionate about fostering innovation and building collaborative environments to unlock the next chapter of success at Proteros.
Lara Kurth
Head of Finance
Lara leads Proteros´ Finance function and is responsible for shaping and overseeing the Financial Strategy, Accounting, Controlling and Tax functions at Proteros. Lara brings a broad range of experience within finance. Before joining Proteros in January 2024, she acted as Vice President at a global Investment Bank, advising mid-sized companies on Mergers & Acquisitions transactions in the Healthcare sector. Prior to that, she was part of KPMG’s M&A advisory team.
Lara holds a Master degree in Accounting and Finance from the University St. Gallen, Switzerland and a B.A. in Business and Economics from the University of Basel, Switzerland.
Christine Lorch
Head of HR
Christine joined Proteros with 20 years of experience in the People and Human Resources field. As the Head of HR, Christine's responsibilities include overseeing the execution of Proteros’ people strategy, focusing on talent attraction, employee engagement, and company culture.
Having worked across innovative sectors, covering additive manufacturing and the software industry, she has a proven track record in delivering people-centric strategies and execution that simultaneously support business priorities. She has successfully supported the scale-up and growth of various international businesses, such as at Bosch Software Innovations or EOS GmbH. Christine has a strong track record of working closely with business leaders to scale and evolve organizations, connecting strategy, talent, and results.
Christine graduated with a law degree from the University of Konstanz and holds a CEP from Science Politiques/IEP Lyon.
